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In a short time, West Nile virus has developed into a nationwide health and veterinary problem. The high virulence of the circulating virus
and related lineage 1 WN strains hinders development of an attenuated live vaccine. We describe an attenuated WN isolate, WN1415, which
is a molecularly cloned descendant of the WN prototype B956 strain. The parent virus belongs to lineage 2, members of which have not been
associated with epidemic or epizootic outbreaks. A set of non-conservative mutations, mostly in non-structural protein genes, distinguishes
the WN1415 isolate from the parent B956 prototype strain. Immunization with WN1415 (55–550,000 pfu) established a potent immunity,
which protected the majority of mice against lethal challenge with WN NY99. The attenuated nature of the isolate and its excellent growth
characteristics combined with the availability of a highly stable infectious clone make the isolate an attractive candidate for live WN vaccine
development.
D 2004 Elsevier Inc. All rights reserved.
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West Nile virus was first isolated over 60 years ago from
the blood of a febrile patient (Smithburn et al., 1940), and it
is one of the most widespread flaviviruses worldwide. The
virus is endemic to Africa and has been repeatedly
registered in Europe and Asia for decades causing self-
limiting epidemics and epizootics (Murgue et al., 2001;
Savage et al., 1999). Recent introduction of the virus into
the naRve environment of the North American continent
(Lanciotti et al., 1999) had disastrous consequences both for
wildlife and human population (Roehrig et al., 2002) and in
a few years has developed into a nationwide epidemiolog-0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: yaximik@ku.edu (V. Yamshchikov).ical problem. In addition to hundreds of human mortality
cases reported to the CDC (CDC, 2004), the virus imposes a
substantial economical burden, especially on the equine
industry (Anonymous, 2003).
A veterinary vaccine of moderate efficacy based on a
formalin-inactivated circulating strain has been developed for
equine immunization (Kahler, 2003; Ng et al., 2003;
Nusbaum et al., 2003). Experimental chimeric vaccines
based on yellow fever 17D and dengue virus vectors have
entered clinical trials (Lai and Monath, 2003). Viable
chimeric flaviviruses carrying WN structural protein genes
induce high titers of virus-specific neutralizing antibodies
and protect mammals against challenge with pathogenic WN
virus (Pletnev et al., 2002; Tesh et al., 2002). YF-based WN
vaccine was not effective in avian species, which is a
consequence of the host restriction imposed by the vector
(Langevin et al., 2003). Cell-mediated immune response
plays an important role in virus clearance and in protection04) 304–312
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Diamond, 2004). Since flavivirus nonstructural proteins
supply the majority of dominant T-cell peptide determinants
(Co et al., 2002), cell-mediated response induced by chimeric
flaviviruses would be mostly to vector proteins. However,
development of a live attenuated WN vaccine, which may
have a better capability to elicit balanced humoral and cell-
mediated immune responses, is hindered by the high
virulence and pathogenicity of the NY99 strain circulating
in the U.S. (Beasley et al., 2002; Roehrig et al., 2002).
Based on serological data and genetic characterization,
West Nile viruses were subdivided into two distinct lineages
(Berthet et al., 1997; Price and O’Leary, 1967). Viruses of
lineage 1, which includes the highly virulent NY99 strain,
are most widespread and often were found in association
with epidemics or epizootics (Roehrig et al., 2002).
Although a few strains with a high virulence were also
found among lineage 2 representatives (Beasley et al.,
2002), viruses of this lineage have not been associated with
disease outbreaks (Lanciotti et al., 1999). For this reason,
lineage 2 viruses may be more attractive for development of
live attenuated West Nile vaccine. We report here the
identification of a potential candidate for development of
such vaccine, which is a descendant of the West Nile virus
prototype B956 (Smithburn et al., 1940) and is one of the
first flaviviruses for which the complete nucleotide
sequence has been determined (Castle et al., 1985, 1986;
Wengler et al., 1985). Earlier, we have reported construction
of the first WN infectious clone designed on the basis of the
isolate 956D117B3, a laboratory derivative of B956
(Yamshchikov et al., 2001). In this report, we demonstrate
that virus recovered from the molecular clone is highly
attenuated, induces vigorous and balanced immune response
and even at low doses protects mice against the virulent
NY99 strain. Combined with its stable genotype and
excellent growth characteristics in tissue culture, the
recovered virus could be used in development of veterinary
and human live West Nile vaccines.Results
Isolation of WN 1415, a molecular clone of the 956D117B3 virus
Isolate 956D117B3 (Wengler and Beato, 1979; Yamsh-
chikov et al., 2001) is a descendant of WN prototype strain
B956 (Smithburn et al., 1940), which since its original
isolation underwent numerous laboratory passages. Subcl-
oned cDNA of this isolate was used to determine the
complete nucleotide sequence of the WN virus genome
(Castle andWengler, 1987; Castle et al., 1985, 1986;Wengler
et al., 1985). In our previous work, the 956D117B3 isolate,
which was considered lost, was rescued from archived RNA
and at Vero passage 2 was used to design the first infectious
clone of WN virus (Yamshchikov et al., 2001). Plasmid
pWN1415, a molecular clone, was used to prepare syntheticRNA, transfection of which into BHK cells gave rise to a
virus designated WN1415. For genetic characterization, total
RNAwas isolated from Vero cells infected with WN1415 at
passage 2 after transfection. Direct sequencing of gel-purified
cDNA fragments prepared from this RNA has revealed two
silent substitutions in positions 4566 (C) and 8355 (U) of the
WN1415 genome as compared to the reported nucleotide
sequence of 956D117B3 (GenBank #M12294); no other
differences were identified. The above substitutions, which
are present in the infectious clone plasmid pWN1415 as
well, likely constitute cDNA variants selected during
cloning. We have verified the nucleotide sequence of the
parent 956D117B3 isolate at Vero passage 2 after its rescue
from archival RNA. Consensus sequencing performed
without intermediate subcloning of cDNA produced a
sequence identical to that reported earlier (GenBank
#M12294), but also revealed several heterogeneous loci
containing minor peaks, which indicated the presence of
quasi-species in the viral population. In contrast, these
heterogeneous loci were not found in the consensus
sequence of the WN1415 clonal isolate characterized at
the same passage level after recovery from RNA, thus
indicating a homogeneous viral population.
Sequence analysis of parent B956 and its descendants
To determine the extent of changes accumulated in the
956B117D3 genome over its passage history, we have
obtained the original B956 strain at mouse brain passage 2.
The virus was passaged once in C6/36 cells and total RNA
isolated from virus-infected cells was used for preparation
of purified cDNA fragments. The nucleotide sequence of
the entire B956 genome was determined without inter-
mediate subcloning of cDNA fragments. Comparison of
the B956 sequence with the reported sequence #M12294
of the 956D117B3 isolate (earlier also referred to as WN-
Nigeria or WN-Wengler (Berthet et al., 1997; Lanciotti et
al., 1999)) revealed 32 point mutations, resulting in 14
amino acid changes spread over the entire genome (Table
1). Most of these amino acid changes accumulated in
NS4A, followed by NS4B, with only 3 found in the
structural protein region, suggesting that most of the
changes are associated with intracellular replication,
presumably with a little or no effect on the virion
properties. The most prominent is a 76 nt deletion in the
3V-UTR beginning after pos. 10391 in the B956 genome,
that is, immediately downstream from the stop codon
terminating the WN open reading frame. Two nucleotide
changes were also found in the 3V-terminal stem-and-loop
structure, which is conserved in flaviviruses and is
important for RNA replication (Proutski et al., 1999).
When the 3V-terminal 110 nucleotides of either sequence
were folded using MFOLD (Zuker, 2003), both these
changes were found in unpaired bulges of the otherwise
completely conserved structure (results not shown) and
thus probably do not play important roles.
Table 1
Summary of sequence differences between B956 and 956D117B3
Positiona Gene B956p2 956D117B3 Change
65 5V-UTR U C –
327 C GCG GCA –
540 prM AUC AUA –
975 E UGC UGU –
1063 E CUA AUA LeuYIle
1548 E ACU ACC –
1577 E GCG GAG AlaYGlu
1819 E AGG CGG LysYArg
3051 NS1 CUG CUA –
3332 NS1 GGA GAA GlyYGlu
3553 NS2A CUG AUG LeuYMet
3609 NS2A AUU AUC –
4328 NS2B GUG GCG ValYAla
4437 NS2B GUU GUG –
5793 NS3 UGC UGU –
5805 NS3 GAC GAU –
6509 NS4A GGG GUG GlyYVal
6620 NS4A GCU GUU AlaYVal
6681 NS4A AAA AAG –
6709 NS4A AUA GUA IleYVal
6846 NS4A GAC GAU –
943 NS4B AGC GGC SerYGly
6954 NS4B UUA UUG –
6962 NS4B AAG AGG LysYArg
7205 NS4B GCC GUC AlaYVal
7218 NS4B GGC GGU –
8290 NS5 GUA AUA ValYIle
9511 NS5 CCC ACC ProYThr
10391 3V-UTR 76 nt insert – –
10399 3V-UTR C U –
10763 3V-UTR U A –
10929 3V-UTR U C –
10948 3V-UTR G U –
a Coordinates according to the 956D117B3 sequence (GenBank
#M12294).
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956D117B3 and viral molecular clone WN1415
956D117B3 and WN1415 display a substantially
decreased cytopathicity as compared to the B956 strain.
In contrast to the latter, both do not form distinguishable
foci of cytopathology (plaques) in Vero cells (Fig. 1 for
WN1415 and B956). However, foci of virus multi-
plication are easily detectable by immunostaining with
the DAB-peroxidase procedure (Fig. 1). Despite the low
cytopathicity, both WN1415 and 956D117B3 grow in
Vero cells to high titers, which in optimal conditions may
reach 108–109 pfu/ml. The more cytopathic B956 strain
produced titers in the range of 107 pfu/ml. There was no
difference between viruses in plaque formation in BHK
cells.
Peripheral virulence was assessed in 4-week-old
outbred mice, which were infected i.m. with 10-fold
virus dilutions. The control group of 6 mice received the
diluent only. As shown in Table 2, 100% mortality could
not be achieved even at highest i.m. dose used. LD50 forWN1415 by this route was found to be 6.6  106 pfu.
The 956D117B3 virus, which was not molecularly
cloned, showed a slightly higher virulence with LD50
of 1.1  106 pfu for i.m. inoculation (Table 2). By the
i.c. route, WN1415 showed LD50 of 158 pfu for adult 7-
week-old mice, but the uncloned 956D117B3 isolate
appeared about 10-fold more neurovirulent with LD50 of
only 13.5 pfu (Table 3). The observed differences may
have resulted from the presence of quasi-species with a
higher virulence in the uncloned 956D117B3 population.
There was no heterogeneity in size of 956D117B3
multiplication foci both in Vero and in BHK cells, which
is consistent with the fact that the RNA from which the
virus was rescued had been extracted from a triple plaque
purified virus (Wengler and Beato, 1979). As mentioned
above, consensus sequencing did reveal several heteroge-
neous loci in the 956D117B3 genome indicative of the
presence of quasi-species, although we did not perform
detailed functional analysis of these. The parent B956
strain was found to be about 50 times more virulent than
WN1415 upon i.m. infection, with LD50 of 1.24  105
pfu (Table 4). In a sharp contrast to the B956 group,
LD50 for NY99 was found to be only 19 pfu (Table 4),
which agrees with earlier reports (Beasley et al., 2002)
documenting the high pathogenicity of this strain. Similar
results were obtained after i.p. inoculation of NY99 as
well (data not shown).
Infection with lethal doses of NY99 uniformly resulted
in rapidly progressing encephalitis accompanied by para-
or even quadriplegia and resolved by death often in less
than 12 h after onset of neurological symptoms. In
contrast, infection with lethal doses of WN1415 resolved
in 2–3 days and was characterized by immobility,
anorexia, and a substantial weight loss, but paralytic
symptoms were uncommon. Neurological symptoms such
as paralysis more often were observed with 956D117B3,
thus corroborating its heterogeneous nature. The provided
evidence indicates that clonal purification of 956D117B3
using the infectious clone technology has yielded the
homogeneous viral clone characterized by a lower residual
virulence in the mouse model.
Virus-specific humoral response
For both 956D117B3 and its WN1415 clonal isolate, the
identity with the NY99 strain is only 79.4% at the
nucleotide level, thus confirming assignment of two strains
to separate lineages (Berthet et al., 1997; Lanciotti et al.,
1999). The overall identity of both viruses at the level of the
amino acid sequence is 93.8%, which is unevenly dis-
tributed among individual proteins (Table 5). At the 94%
sequence identity between envelope proteins of NY99 and
WN1415, induction of cross-reactive antibodies and a
certain level of cross-protective immunity could be
expected. To evaluate that, titers of NY99 cross-reacting
antibodies and the neutralizing activity of the immune sera
Fig. 1. Cytopathic properties of the WN prototype strain B956 and the clonal isolate WN1415. BHK (top panel) or Vero (lower panel) monolayers were
infected with 10-fold dilutions of corresponding viruses and incubated under 1% methylcellulose overlays for 4–5 days. Cells fixed with 1% HCHO were
stained with Coumassie G250, washed, dried and photographed in visible light (left panels for each virus). Coumassie stain was removed with ethanol washes,
and monolayers were rehydrated in 50% alcohol followed by PBS. Virus foci were immunostained as described in Materials and methods and photographed in
visible light (right panels for each virus).
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survived immunization with 956D117B3 or WN1415. Both
956D117B3 and NY99 antigens produced very similar
readings with the tested sera in ELISAs specific for antiviral
IgG. The levels of WN-specific IgG at 3 weeks post-
immunization with WN1415 and at 2 weeks post-challenge
with NY99 are shown in Fig. 2 as endpoint dilutions of
averaged sera yielding positive readouts with the NY99
antigen. Higher virus doses resulted in earlier appearance of
WN-specific antibodies (data not shown), and all survived
mice developed detectable antiviral humoral immunity by 3
weeks post-infection, in serum dilutions ranging from 400
to 6400 depending on virus dosage. By this time, mice in all
dosage groups have already demonstrated substantial titers
of neutralizing antibodies against the NY99 strain (Table 6).
Thus, combination of virus IgG-specific ELISA and data on
neutralizing antibody titers confirmed the high antigenic
similarity of both viruses, and suggest that efficientTable 2
Virulence of WN1415 and 956D117B3 in NIH Swiss mice by the i.m. route
WN1415a D/Tb %b 956D117B3a D/Tb %b
4.9E + 07 5/6 83 4.0E + 07 4/6 66
4.9E + 06 2/6 33 4.0E + 06 4/6 66
4.9E + 05 1/6 17 4.0E + 05 3/6 50
4.9E + 04 1/6 17 4.0E + 04 1/6 17
4.9E + 03 0/6 0 4.0E + 03 0/6 0
4.9E + 02 0/6 0 4.0E + 02 0/6 0
0 0/6 0 0 0/6 0
LD50 = 6.62E + 06 LD50 = 1.13E + 06
a pfu per mouse.
b Mortality after 2 weeks (D/T—dead/total).protection against NY99 infection may be expected after
WN1415 immunization as well.
Immunization with WN1415 confers strong protection
against NY99 challenge
Three weeks after inoculation with various doses of
WN1415 (as shown in Table 7), all survived mice were
challenged i.m. with 10 LD50 of NY99 strain. Eighty-five
percent of mice, which had survived the WN1415 infection,
have survived the lethal challenge with NY99, whereas
none survived in the control group (Table 7). Although
100% protection was observed only in mice that received
the two highest doses of WN1415, 67% of mice immunized
with only 55 pfu of WN1415 where able to fend off the
infection. During the 2-week observation period after the
challenge, neither of mice that survived the challenge have
displayed any signs of disease, such as immobility, ruffled
fur, or anorexia, while all mice in the control group have
succumbed to paralytic encephalitis between 8 and 11 daysTable 3
Infectivity of WN1415 and 956D117B3 in NIH Swiss mice by the i.c. route
WN1415a D/Tb %b 956D117Ba D/Tb %b
– – – 5.2E + 03 3/3 100
5E + 02 3/3 100 5.2E + 02 6/6 100
5E + 01 0/3 0 5.2E + 01 5/6 83
5E + 00 0/3 0 5.2E + 00 1/3 33
5E01 0/3 0 – – –
LD50 = 1.58E + 02 LD50 = 1.35E + 01
a pfu per mouse.
b Mortality after 2 weeks (D/T—dead/total).
Table 4
Virulence of B956 and NY99 in NIH Swiss mice by the i.m. route
B956a D/Tb %b NY99a D/Tb %b
2.2E + 06 5/6 83 – – –
2.2E + 05 4/6 66 1E + 05 6/6 100
2.2E + 04 1/6 17 1E + 04 6/6 100
2.2E + 03 0/6 0 1E + 03 5/6 83
2.2E + 02 0/6 0 1E + 02 5/6 83
2.2E + 01 0/6 0 1E + 01 3/6 50
0 0/6 0 0 0/6 0
LD50 = 1.24E + 05 LD50 = 1.93E + 01
a pfu per mouse.
b Mortality after 2 weeks (D/T—dead/total).
Fig. 2. Development of WN-specific IgG response. Four weeks old NIH
Swiss mice were immunized i.m. with indicated doses of WN1415 and sera
collected at 3 weeks post-infection and at 2 weeks post-challenge with 10
LD50 of WN NY99. Serum samples were assayed by ELISA for WN-
specific IgG using the NY99 viral antigen and endpoint dilution values
were averaged for survivors in each of the WN1415 dosage groups. Pre-
and post-challenge IgG titers were compared using standard T-test. In the
three highest WN1415 dosage groups, mice did not display statistically
significant changes in the titer of virus specific antibodies after the
challenge (p N 0.05), as compared to mice in the two lowest dosage group
( P b 0.05; see text for details).
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mice did not display statistically significant changes in the
titer of virus specific antibodies after the challenge (Fig. 2),
indicating that infection with NY99 was very limited or was
completely suppressed. In contrast, mice that survived the
challenge in the two lowest WN1415 dosage groups did
show a significant increase in average antibody titers by 2
weeks after challenge (Fig. 2, P values 0.026 and 0.022 for
5.5E + 02 and 5.5E + 01 pfu correspondingly), indicating
that infection with NY99 virus was not prevented. However,
we have not observed any disease symptoms in these mice.
Whether immunization with lower doses of WN1415 has
induced a potent cell-mediated immunity, which has helped
to curb and eventually eliminate infection, requires a more
detailed investigation.
Inoculation with the more virulent 956D117B3 isolate
resulted in a higher mortality rate (Table 2), but has also
conferred a stronger protection upon survived mice since
100% survival was observed in all dosage groups after i.p.
challenge with 10-fold higher doses of NY99 (100 i.p.
LD50; Table 7). While older mice have been used in this
experiment, the age did not appear to contribute to the
observed increase in survival since the challenge with NY99
still resulted in 100% mortality in the control group of mice
(Table 7). These data suggest that more virulent quasi-
species present in the 956D117B3 population may have
substantially increased the potency of the preparation. On
the other hand, while less virulent WN1415 has obviously
lost some potency, it was still able to induce a sufficient
protection in immunized animals.Discussion
Despite tremendous advances in our understanding of
viral replication and pathogenesis, the attenuation process asTable 5
The identity of WN strains NY99a and WN1415b at the protein level
C prM(M) E NS1 NS2A
% identity 97 96 (96) 94 92 89
a GenBank #AF196835.
b GenBank #M12294.a methodology of vaccine design continues to rely on a
poorly rationalized and largely empirical approach. Beyond
YF17D, only a few more attenuated flavivirus vaccines have
been licensed for human use or have reached the level of
human clinical trials elsewhere in the world (reviewed,
(Pugachev et al., 2003)). The rational approach has been
more successful in design of chimeric or subunit vaccines
(Eckels and Putnak, 2003; Lai and Monath, 2003), which
despite efficient stimulation of humoral immunity remains
much less efficient by design in induction of virus-specific
cell-mediated immune responses. For this reason, develop-
ment of the most potent attenuated virus vaccines remains
an important and viable alternative.
In this report, we described the WN1415 molecular viral
clone that is a descendant of the West Nile prototype strain
B956. WN1415 was produced from 956D117B3 isolate of
B956 virus using molecular infectious clone technology.
956D117B3 has undergone numerous passages and differs
from the parent strain both by genotype and phenotype,
including the lower cytopathicity in cell culture and a reduced
virulence in mice. The majority of amino acid substitutions
were found in nonstructural proteins and in the 3V-untrans-
lated region suggesting changes at the intracellular stage of
viral replication. However, the non-conservative change
AlaYGlu at pos. E204 might also contribute to attenuation.NS2B NS3 NS4A NS4B NS5
98 96 93 91 95
Table 6
Development of NY99 neutralizing immunitya after WN1415 immunizationb
Mouse
No.
WN1415 dose, pfu/mouse
5.5E + 05 5.5E + 04 5.5E + 03 5.5E + 02 5.5E + 01
1 160 ND 320 160 ND
2 80 320 80 80 ND
3 ND 160 160 40 160
4 160 80 ND ND 160
5 160 ND ND 80 ND
6 40 320 640 160 40
a NY99 neutralizing titer at 3 weeks post-immunization.
b ND—mice died after either the primary immunization, or the challenge,
or for unrelated reasons.
Table 7
Survival of immunized mice after NY99 challenge
WN1415a S1/S2b %b 956D117B3a S1/S2b %b
5.5E + 05 5/5 100 1E + 06 2/2 100
5.5E + 04 4/4 100 1E + 05 4/4 100
5.5E + 03 5/4 80 1E + 04 4/4 100
5.5E + 02 6/5 83 1E + 03 5/5 100
5.5E + 01 6/4 67 1E + 02 5/5 100
0 6/0 0 0 6/0 0
NY99 dose: 10 LD50, i.m. NY99 dose: 100 LD50, i.p.
a Primary immunization, pfu/mouse.
b S1—survived after primary immunization; S2—survived the challenge.
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the dimerization domain (Rey et al., 1995), and both more
virulent B956 and NY99, as well as all JE viruses sequenced
to date contain an uncharged amino acid at this position. On
the other hand, attenuation does not always result in
accumulation of mutations in the E protein (Kinney et al.,
1997), and several non-conservative changes found in NS1,
NS4B and NS5, as well as the 76 nt deletion in 3V-NTR may
contribute to attenuation at the level of RNA replication or
other stages of the virus infectious cycle.
Lineage 2 WN viruses have not been associated with
epidemic or epizootic outbreaks (Lanciotti et al., 1999),
although a few virulent isolates have been identified at the
WHO Collaborating Center for Tropical Diseases (Beasley
et al., 2002) in collection of WN strains isolated between
1950 and 1999 from various hosts. The B956 strain itself is
6,500-fold less virulent as compared to NY99 strain (LD50
are 1.24  105 and 19 pfu for B956 and WN NY99,
respectively, for peripheral inoculation) and its additional
50-fold attenuation makes WN1415 (LD50 = 6.62  106) an
attractive candidate for development of an attenuated WN
vaccine. Similar to the YF17D vaccine, which showed i.c.
LD50 of 0.3 to 5.9 pfu depending on manufacturer
(calculated based on Monath, 1999), the WN1415 isolate
remains neurovirulent for adult mice after i.c. inoculation.
It was not clear whether a lineage 2 virus is capable to
induce a strong protective immunity against the highly
pathogenic lineage 1 NY99 strain and will not result in an
opposite effect of the immune enhancement, which had been
described for homologous and heterologous viruses of the
JE serocomplex and WN in particular both in mice
(Fagbami et al., 1987; Gollins and Porterfield, 1985; Lobigs
et al., 2003) and observed with sera of naturally immunized
human population (Fagbami et al., 1988). The sequence
identity between E proteins of two viruses is 94%
corresponding to 30 aa differences (including a 4-aa deletion
encompassing the only glycosylation site in the E protein)
out of 501 amino acids composing the E protein of NY99.
Recently reported variation in the neutralizing capacity
toward another lineage 2 WN strain H-442 of three NY99
monoclonal antibodies (MAbs) corroborate antigenic differ-
ences between the two lineages (Beasley and Barrett, 2002).Interestingly, however, that for the tested MAbs, two out of
three experimentally determined epitope-defining positions
(E307 and E330, (Beasley and Barrett, 2002)) appeared
identical in both tested strains (GenBank #AF459403 and
#AF196835), indicating that analyzed neutralizing epitopes
were not linear and the linear homology has a limited
predictive value in estimation of the antigenic similarity.
The present evidence indicates that immunization with
attenuated derivatives of B956, the 956D117B3 isolate and
its clonal variant WN1415, induces potent immune
responses capable of protecting against infection with the
highly virulent NY99 strain. Immunization with doses in the
range of 5.5  103 to 5.5  105 pfu of WN1415 (roughly
equivalent to 35–3500 mouse i.c. LD50) induced a
substantial level of NY99 neutralizing antibodies detectable
as early as 3 weeks post-immunization and the resulting
immunity protected almost all immunized animals from
infection with NY99. Although a direct comparison cannot
be made, a single human dose of YF17D vaccine is required
to contain at least 1000 mouse i.c. LD50 (WHO, 1998), but
in fact, most preparations contain between 5000 and 10,000
LD50 per dose (Barrett, 1997). The majority of mice
immunized with doses 55–550 pfu (0.35–3.5 mouse i.c.
LD50) also withstood the challenge, even though the
infection was not prevented as indicated by the several fold
increase in post-challenge IgG titers. Since cell-mediated
immunity plays a major role in clearance of viral infection
(Engle and Diamond, 2003; Murphy and Chanock, 1996),
one may suggest that immunization with lower doses of
WN1415 induced a cell-mediated response strong enough to
terminate developing infection. Studies on the status of cell-
mediated immunity after immunization with WN1415 are
currently under way.
The more virulent 956D117B3 isolate has shown a
higher potency in our study, protecting all mice even in the
group immunized with a dose of 10 pfu. Perhaps, due to its
higher potency, the 956D117B3 isolate may seem a better
candidate for further development of a WN vaccine.
However, its unknown passage history is a major stumbling
block for its use in vaccine development. In contrast, the
WN1415 virus can be recovered again from infectious RNA
and further propagated using approved substrates to create a
defined passage history. We have used the molecular
cloning technology to improve homogeneity of the viral
G. Yamshchikov et al. / Virology 330 (2004) 304–312310population and eliminate adventitious agents, which could
be carried over its passage history. The pWN1415 infectious
clone was reconstructed from molecularly cloned cDNA
fragments, and the virus with the predominant genotype was
rescued from synthetic RNA (Yamshchikov et al., 2001).
The obtained more homogenous viral population displayed
a decreased virulence in the mouse model, which is not
necessarily a trivial result considering that an earlier attempt
to apply the molecular clone technology to improve the
safety profile of the YF17D vaccine had yielded a more
virulent isolate (Marchevsky et al., 1995).
Despite already achieved the relatively high level of
attenuation, the WN1415 virus still causes limited mortality
of infected animals when used at high doses. The existing
attenuated vaccines approved for human use, JE SA14-14-2
and YF17D, do not cause mortality upon peripheral
inoculation of adult mice. WN and JE viruses belong to one
serological group, and genetic basis of SA14-14-2 attenu-
ation is well established (Aihara et al., 1991; Arroyo et al.,
2001a; Monath et al., 2002; Ni and Barrett, 1996; Ni et al.,
1995; Wu and Lee, 2001). It was noted that virulent JE and
WN strains contain identical amino acids in E protein loci that
are crucial for JE attenuation (Arroyo et al., 2001b;Monath et
al., 2001, 2002). This defines a feasible approach for further
attenuation of the WN1415 vaccine candidate.
While attenuation of the NY99 virus or its closer
lineage 1 homologue presumably could provide a better
match for development of a WN vaccine, this approach is
immensely complicated by the very high and age-
independent virulence and pathogenicity of this strain
(Beasley et al., 2002). Several strains of Kunjin virus, an
Australian antigenic relative of lineage 1 WN viruses
(Scherret et al., 2001), have displayed a reduced virulence
in the mouse model (Beasley et al., 2002), but their
protective potential against NY99 infection has yet to be
evaluated. The efficient protection induced after immuni-
zation with the attenuated molecular clone WN1415,
strengthened by the availability of its highly stable
infectious clone, and combined with the current knowledge
of flavivirus attenuation may bring the goal of WN vaccine
design within a practically reachable limits.Materials and methods
Cells and viruses
BHK-21 cells (Bredenbeek et al., 1993) and Vero (ATCC
CRL-1586) were maintained at 37 8C in a humidified
atmosphere containing 5% CO2 in Dulbecco’s modified
Eagle medium (DMEM) supplemented with 5% fetal calf
serum (FCS; Hyclone, Logan, UT) and 1 antibiotic–
antimycotic mixture (Invitrogen, Carlsbad, CA). WN strain
956D117B3 was recovered after transfection of BHK cells
with archival RNA (Wengler and Beato, 1979; Yamshchi-
kov et al., 2001) and was used after an additional passage inVero cells. Isolate WN1415 used in this study was recovered
after transfection of synthetic RNA prepared from the
pSP6WN/Xba infectious clone (Yamshchikov et al., 2001)
into BHK cells and was used at passage 2 in Vero cells. The
prototype WN strain B956 (at mouse brain passage 2) and a
385–99 isolate of the NY99 strain (at Vero passage 1) were
generously provided by Drs. R. Shope and R. Tesh
(Galveston, TX), respectively. The viruses were grown
once in C6/36 cells and were used after an additional
passage in Vero and C6/36 cells, respectively.
Nucleotide sequence determination
Consensus sequencing (Pugachev et al., 2002) was done
after RT-PCR amplification of eight overlapping cDNA
fragments spanning the entire genome of WN1415,
956D117B3 or B956 viruses. The gel-purified fragments
were sequenced without intermediate subcloning steps using
the ABI310 Genetic Analyzer (ABI, Foster City, CA). A set
of sequencing primers was designed to provide overlapping
sequence segments covering the entire genome in both
directions. Contiguous sequences were assembled with
AutoAssembler 2.0 software (ABI) and downstream
sequence analysis was done with the VectorNTI Advance
suite (InforMax, Bethesda, MD). Folding of 3VNTR segment
of genomic RNA was done with the MFOLD program
available on-line (Zuker, 2003). Sequence of the prototype
B956 strain is deposited in the GenBank under accession
#AY532665.
Virus infection and challenge
Swiss Webster (ICR) or NIH Swiss outbred mice were
purchased from Hilltop Lab Animals Inc. (Scottsdale, PA)
and Harlan Sprague–Dawley (Indianapolis, IN), respec-
tively, maintained in a BL3 facility according to the NIH
guidelines, and used in IACUC-approved protocols. Mice
were anesthetized with metofane (Mallinckrodt Veterinary,
Mundelein, IL) and infected into the Tibialis anterior
muscle (i.m.) or intracerebrally (i.c.) with virus diluted in
PBS plus 0.2% of normal mouse serum. LD50 (50% lethal
dose) was calculated by the Reed and Muench method
(Burleson et al., 1992). For challenge experiments, anes-
thetized mice were inoculated i.m. with 10 i.m. LD50 (unless
specified otherwise) of NY99 virus. Mice were observed
daily for the development of encephalitis and mortality.
Moribund mice were euthanased.
Analysis of antibody response
For ELISA, the coating antigen was prepared from
956D117B3 or NY99 viruses pelleted through 20%
sucrose cushion from media of infected Vero cells. The
3-h centrifugation at 25,000 rpm was done using a
Beckman SW28 rotor. The pellet was resuspended in 50
mM triethanolamine–HCl pH 8.5, 100 mM NaCl, and
G. Yamshchikov et al. / Virology 330 (2004) 304–312 3110.5% Triton X-100 to extract viral envelope subunit
antigen (Heinz et al., 1981). Clarified supernatant
(1000  g, 15 min, 4 8C) was stored at 80 8C and
was used at 1:500 dilution in PBS. Serial 2-fold dilutions
of immune sera were tested in duplicate using a goat anti-
mouse IgG(H + L) peroxidase conjugate with the TMB
substrate (Sigma-Aldrich, St. Louis, MO). Assays were
read at 450 nm using PowerWave XS microplate reader
equipped with KC-4 software (Bio-Tek, Winooski, VT).
Readings of two standard deviations above the background
(serum from control mice used at the same dilution) were
considered positive.
Virus titration and plaque reduction-neutralization (PRNT)
assays
Virus titers were determined by a microplate method.
Serial 10-fold dilutions of virus stocks in DMEM containing
0.5% FCS were prepared in duplicate wells of a 96-well
cluster and 50 Al was transferred in parallel to confluent
monolayers of Vero cells in 96-well plates using a multi-
channel pipettor. The plates were incubated for 1 h at 37 8C
in the CO2 incubator with occasional shaking. The inocula
were aspirated, replaced with 100 Al of the growth medium,
and plates returned to the incubator for additional 24 h.
Under these conditions, virus multiplication foci consisted
of compact clusters of 5–15 cells, which stained positive for
the viral antigen as described below.
PRNT assays were done in a similar microplate format.
Two-fold dilutions of immune sera in DMEM + 0.5% FCS
were mixed in duplicate in 96 well plates with equal volume
of NY99 virus prediluted in the same medium to 2  103
pfu/ml and the plate was kept in CO2 incubator at 37 8C for
1 h. Fifty microliters of each mix (containing about 50 pfu)
was transferred in parallel into a 96-well plate with
confluent Vero monolayers and incubated for another hour
as above. The inocula were aspirated, replaced with 100 Al
of the growth medium and plates returned to the incubator
for 24 h.
At the end of the incubation period, cells were fixed by
addition of 25 Al/well of 10% formalin in PBS and
incubation for 30 min at room temperature. Foci of viral
multiplication were visualized on fixed monolayers with
DAB substrate (Vector Laboratories, Burlingame, CA) after
the following treatment sequence (50 Al/well): 0.5% Thesit
(Sigma-Aldrich) for 10 min, 1:1000 dilution of WN mouse
hyperimmune antiserum for 30 min, 1:1000 dilution of
biotinylated horse anti-mouse IgG(H + L) (Vector Labo-
ratories) for 30 min, 2 Ag/ml streptavidin (ICN, Aurora, OH)
for 30 min, 3.5 Ag/ml biotinylated peroxidase (ICN) for 30
min. PBS supplemented with 1% horse serum was used as a
diluent throughout the assay, and plates were washed
extensively in tap water between treatments. For PRNT,
endpoint serum dilutions providing 50% reduction in the
number of foci over control wells that contained no immune
serum were counted as positive.Acknowledgments
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